Log In
Print
BCIQ
Print
Print this Print this
 

RXDX-105 (formerly CEP-32496)

  Manage Alerts
Collapse Summary General Information
Company Daiichi Sankyo Co. Ltd.
DescriptionSmall molecule inhibitor of BRAF, EGFR and RET
Molecular Target BRAF ; Epidermal growth factor receptor (EGFR)
Mechanism of ActionRET inhibitor; BRAF inhibitor; Epidermal growth factor (EGF) receptor inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I/II
Standard IndicationMelanoma
Indication DetailsTreat melanoma
Regulatory Designation

Partner

Ignyta Inc.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

4

$40.6M

$2.3M

$27.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today